meaningful use workgroup
Post on 22-Feb-2016
35 Views
Preview:
DESCRIPTION
TRANSCRIPT
Paul Tang, ChairGeorge Hripcsak, Co-Chair
Meaningful Use Workgroup
January 6, 2014
Meaningful Use Workgroup Members
Chairs• Paul Tang , Palo Alto Medical Foundation• George Hripcsak, Columbia UniversityMembers• David Bates , Brigham and Women’s Hospital• Christine Bechtel , National Partnership for
Women & Families• Neil Calman , The Institute for Family Health• Arthur Davidson, Denver Public Health
Department• Paul Egerman, Businessman/Entrepreneur• Marty Fattig, Nemaha County Hospital
Auburn, Nebraska • Leslie Kelly Hall, Healthwise• David Lansky, Pacific Business Group on
Health• Deven McGraw , Center for Democracy &
Technology
• J. Marc Overhage, Siemens Healthcare• Patricia Sengstack, Bon Secours Health
Systems• Charlene Underwood, Siemens• Michael Zaroukian, Sparrow Health
System• Amy Zimmerman, Rhode Island Office of
Health & Human ServicesFederal Ex officios• Tim Cromwell, Department of Veterans
Affairs• Joe Francis , Veterans Administration• Greg Pace, Social Security Administration• Martin Rice, HRSA• Robert Tagalicod, Centers for Medicare &
Medicaid Services, HHS
2
Workplan
Date Meeting Tasks1/6/2014
9:30-11:30 ET• Standards feedback
• PGHD• Medication Adherence
• Open Notes• Affordable care • Health disparities
1/17/1411:00-1:00 ET
• Follow-up items• Review of recommendations
1/28/141:00-3:00 ET
• Follow-up items• Review of recommendations
2/4/14 • Present to HITPC
3
4
Feedback from HITSC - PGHD
Engaging patients and families in their care: Patient Generated Health Data
5
Stage 3 Functionality Goals
• Enabling active participation by patients and families to improve health and care
• Provide ability to contribute information in the record, including patient reported outcomes (PRO)
• Patient preferences recorded and used
Functionality Needed to Achieve Goals
• Eligible Providers and Hospitals provide the capability for patients to electronically submit patient-generated health information through structured or semi-structured questionnaires (e.g., screening questionnaires, intake forms, risk assessment, functional status), secure messaging or provider-selected devices using CEHRT. (Provider-selected devices pending consideration by HITSC)
• Recommended as a Menu item• Low threshold
Standards Recommendations
• ONC should consider the Direct transport standard for secure messaging and data from devices
• ONC should consider the HL7 Care Team Roster standard
• ONC should consider the HL7-CCDA for structured and unstructured questionnaires
• ONC should consider the Continua standard for data from devices
• We encourage standards that support mobile access to patient data and PGHD given the proliferation of mobile devices. However, we do not recommend mandating a specific standard at this time given that might stifle innovation.
6
HITSC Discussion
• The key discussion was an evaluation of the standards maturity and the level of adoption of the standards suggested for patient generated data. Recommendations included Direct for data transport, CCDA for content capture, LOINC/SNOMED for vocabulary capture, and Continua implementation guides for devices.
• As a followup the Consumer Technology Workgroup will list examples of CCDA templates that can be used to support patient generated data use cases.
• Continua will provide a list of the named standards so that we can validate the maturity and adoption of Continua's recommendation.
• We will also ensure that the CCDA templates include the appropriate vocabularies that will enable incorporation of patient generated data into EHRs.
• http://geekdoctor.blogspot.com/2013/12/the-december-hit-standards-committee.html
7
8
Medication AdherenceHITSC Clinical Quality Workgroup
Marjorie Rallins, Co-ChairDanny Rosenthal, Co-Chair
Questions presented to CQWG from MUWG
Updated Stage 3 Objective QuestionMedication adherence certification criteria: • Ability to accept data feed from PBM (Retrieve external medication fill
history for medication adherence monitoring)• Ability to identify important signals such as:
• identify data that patient is not taking a drug• patient is taking two kinds of the same drug (including detection
of abuse) or • multiple drugs that overlap
Certification criteria: EHR technology supports streamlined access to prescription drug monitoring programs (PDMP) data.• For example: Via a hyperlink or single sign-on for accessing the PDMP data Via automated integration into the patient’s medication history • Leveraging things like single sign on or functionality that could enable
the linkage between PDMPs and prescribers and EDs?
Clinical Quality: feedback on the readiness of standards will help determine whether this could be a certification criteria item for stage 3 or should be pushed out to a future stage.
9
CQWG: Recommendations/Comments for Medication Adherence (I)
1. Suggest further clarification on the goals of MU for medication adherence and prescription drug monitoring. Once clarified, prioritize goals
2. The following standards could be recommended for medication adherence. Note, original intent of the standards were for administrative analysis. Clinical use may require further cleaning of the data
a. NCPDP SCRIPT Standardb. NCPDP Structured and Codified Sig Format (component to be used
with NCPDP SCRIPT Standard)c. RxNorm. EHR should be able to accept RxNorm codes
3. NDF-RT considered but limited to drug class identification
10
Recommendations/Comments (II)
Other comments and recommendationsa. Signals can be identified but are not necessarily computable; b. Actions on signals are out of scope for this questionc. C-CDA medication list; reconciliation should be considered in the context
of medication adherenced. Various states accumulate data on controlled substances and make that
data available to providers that have no data integration with other systems
e. Alignment of goals medication adherence and prescription drug monitoring with other regulatory activity and other agencies (e.g., FDA is crucial)
f. MUWG should have direct communication with an NCPDP expert (e.g., Lynn Gilbertson, Vice President, Standards Development, NCPDP)
CQWG: Recommendations/Comments for Medication Adherence (II)
11
CQWG: Recommendations/Comments for PDMP
• Many issues remain under consideration for prescription drug monitoring standards.
• As such, CQWG cannot recommendations at this time
12
13
Open Notes
Follow-up from clinical documentation hearing
• To improve accuracy, to improve patient engagement, and to guard against fraud, EHRs should have the functionality to provide progress notes as part of MU objective for View, Download, and Transmit
• OpenNotes– http://www.myopennotes.org/– Recent NEJM article
14
15
Affordable Care
Affordable care:Stage 3 Priorities
16
• CDS support to avoid duplicative care
• CDS support to avoid unnecessary or inappropriate care
MU Outcome Goals
• Eliminate duplicative testing
• Use cost-effective diagnostic testing and treatment
• Minimize inappropriate care (overuse, underuse, and misuse)
• Formulary checks• Generics
Stage 3 Functionality Goals MU Outcome GoalsStage 1 + 2 Functional
Objectives
Affordable care:Clinical Decision Support
17
Examples of Functionality Needed to Achieve Goals
• Demonstrate use of multiple CDS interventions that apply to quality measures in each of the six NQS domains. Recommended interventions include: – Preventive care– Chronic disease management (e.g., diabetes,
coronary artery disease) – Appropriateness of lab and radiology orders – Advanced medication-related decision support
(e.g., renal drug dosing) – Improving the accuracy/completeness of the
problem list– Drug-drug and drug-allergy interaction checks
• CEHRT should provide tools that enable the ability to provide these interventions
• Related work that can inform: S&I HealtheDecisions, HITSC Clinical Quality WG
Stage 3 Functionality Goals
• CDS support to avoid duplicative care
• CDS support to avoid unnecessary or inappropriate care
Reducing Health Disparities
18
Reducing health disparities:Stage 3 Priorities
19
• Patient conditions are treated appropriately (e.g. age, race, education, LGBT)
MU Outcome Goals
• Eliminate gaps in quality of health and health care across race, ethnicity, and sexual orientation
• Language• Gender • Race• Ethnicity
Stage 3 Functionality Goals MU Outcome GoalsStage 1 + 2 Functional
Objectives
Reducing health disparities:Additional Patient Information
20
Functionality Needed to Achieve Goals
• CEHRT provides the ability to capture– Patient preferred method of communication*– occupation and industry codes– Sexual orientation, gender identity (optional fields) – Disability status
o Differentiate between patient reported & medically determined
• Communication preferences will be applied to the clinical summary, reminders, and patient education objectives – Providers should have the ability to select options that are
technically feasible for them, these could include: Email, text, patient portal, telephone, regular mail
• Recommended as certification criteria only
Stage 3 Functionality Goals
• Patient conditions are treated appropriately (e.g. age, race, education, LGBT)
Reduction of Disparities – previous deeming recommendations
• Reduction of disparities in gap area• Identify areas where attesters should be
required to demonstrate they have reduced health care disparities in high-risk populations
21
top related